Interleukin-1 receptor antagonist - PharmaciaAlternative Names: Interleukin-1 receptor antagonist protein; IRAP; Recombinant human interleukin-1 receptor antagonist protein; Recombinant interleukin-1 receptor antagonist protein; rIRAP
Latest Information Update: 28 Feb 1996
At a glance
- Originator Pharmacia Corporation
- Class Anti-inflammatories; Antirheumatics
- Mechanism of Action Interleukin 1 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Inflammation; Rheumatic disorders; Type 1 diabetes mellitus